Presentation of positive preclinical results for a new formulation of
arsenic trioxide for the treatment of graft-versus-host disease - cGvHD - and other severe autoimmune diseases.

MEDSENIC receives a notice of allowance in the United States for a new patent that extends the use of arsenic trioxide to the treatment of relapsing forms of multiple sclerosis.

Medsenic announces positive results from its Phase II clinical trial for the treatment of chronic graft versus host disease...